Respiratory syncytial virus immunization with nirsevimab: Acceptance and satisfaction assessment in infants and risk groups in the region of Murcia (Spain).

Abstract

Respiratory syncytial virus (RSV) is a leading cause of respiratory infections in infants under two years of age, often resulting in bronchiolitis and pneumonia, which contribute to high hospitalization rates. The recent approval of nirsevimab, a long-acting monoclonal antibody, has provided an immunization alternative for infants, addressing the substantial burden of RSV. This study aimed to evaluate acceptance and satisfaction among parents or legal guardians of infants who were candidates for immunization with nirsevimab in the Region of Murcia (Spain) during the 2023-2024 campaign. A cross-sectional survey, encompassing 1692 parents of immunized infants and 219 of non-immunized infants, revealed a high acceptance rate for nirsevimab, with 87% of parents indicating willingness to immunize a future child and 86.6% willing to recommend it. Concerns about safety and side effects were the primary reasons for hesitation among parents who did not immunize their infants. These findings underscore the importance of enhancing educational efforts in future campaigns to address safety concerns, thereby supporting broader RSV immunization coverage in the pediatric population.